Pemetrexed + Carboplatin + Olomorasib + PEMBROLIZUMAB + Cetuximab + CISPLATIN for endometrial neoplasms

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 1 trial. Early trial in people, checking safety. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 9 Jul 2021: Trial registered, NCT04956640
  2. 19 Jul 2021: Trial started, NCT04956640

The trials

NCT04956640: Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)

State
Under way
Phase
Phase 1 and Phase 2
People
540 planned
Started
19 Jul 2021
Primary completion
Apr 2027
Arms
LY3537982 (Dose Expansion)
Results
None posted
  1. 9 Jul 2021: Trial registered
  2. 19 Jul 2021: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 1 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.